转移性乳腺癌：哪些人从手术中获益？
Metastatic breast cancer: Who benefits from surgery?
机构信息
Duke University Medical Center, Department of Surgery, Durham, NC, USA.
Duke Cancer Institute, Durham, NC, USA; Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, USA; Duke University, Department of Biostatistics & Bioinformatics, Durham, NC, USA.
出版信息
Am J Surg. 2022 Jan;223(1):81-93. doi: 10.1016/j.amjsurg.2021.07.018. Epub 2021 Jul 22.
Abstract
BACKGROUND
We sought to identify characteristics of metastatic breast cancer (MBC) patients who may benefit most from primary tumor resection.
METHODS
Recursive partitioning analysis (RPA) was used to categorize non-surgical patients with de novo MBC in the NCDB (2010-2015) into 3 groups (I/II/III) based on 3-year overall survival (OS). After bootstrapping (BS), group-level profiles were applied, and the association of surgery with OS was estimated using Cox proportional hazards models.
RESULTS
All patients benefitted from surgery (median OS, surgery vs no surgery): 72.7 vs 42.9 months, 47.3 vs 30.4 months, 23.8 vs 14.4 months (all p < 0.001) in BS-groups I, II, and III, respectively. After adjustment, surgery remained associated with improved OS (HR 0.52, 95% CI 0.50-0.55). The effect of surgery on OS differed quantitatively across groups.
CONCLUSION
Prognostic groups may inform the degree of benefit from surgery, with the greatest benefit seen in those with the most favorable survival.
摘要
背景
我们旨在确定可能从原发肿瘤切除中获益最大的转移性乳腺癌（MBC）患者的特征。
方法
基于 3 年总生存（OS），递归分区分析（RPA）将 NCDB（2010-2015）中初诊为 MBC 的非手术患者分为 3 组（I/II/III）。在引导（BS）后，应用组级分析，使用 Cox 比例风险模型估计手术与 OS 的相关性。
结果
所有患者均从手术中获益（中位 OS，手术 vs 非手术）：BS 组 I、II 和 III 中的 72.7 与 42.9 个月、47.3 与 30.4 个月、23.8 与 14.4 个月（均 p<0.001）。校正后，手术仍与 OS 改善相关（HR 0.52，95%CI 0.50-0.55）。手术对 OS 的影响在组间存在定量差异。
结论
预后分组可以告知手术获益的程度，在生存最有利的患者中获益最大。
相似文献
1
Metastatic breast cancer: Who benefits from surgery?转移性乳腺癌：哪些人从手术中获益？
Am J Surg. 2022 Jan;223(1):81-93. doi: 10.1016/j.amjsurg.2021.07.018. Epub 2021 Jul 22.
2
Breast surgery for young women with early-stage breast cancer: Mastectomy or breast-conserving therapy?早期乳腺癌年轻女性的乳房手术：乳房切除术还是保乳治疗？
Medicine (Baltimore). 2021 May 7;100(18):e25880. doi: 10.1097/MD.0000000000025880.
3
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.接受一线曲妥珠单抗为基础治疗的新诊断 IV 期或复发性 HER2 阳性转移性乳腺癌患者的治疗模式和临床结局：一项多中心回顾性队列研究。
Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.
4
Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.曲妥珠单抗为基础的治疗用于 HER2 阳性初治或复发的 IV 期乳腺癌女性的临床结局。
Breast. 2014 Feb;23(1):44-9. doi: 10.1016/j.breast.2013.10.005. Epub 2013 Nov 7.
5
Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.AJCC 第 8 版分期系统对 T1-2N1 乳腺癌患者选择术后放疗的有效性：来自两个机构的 1986 例患者的联合分析。
BMC Cancer. 2020 Aug 24;20(1):792. doi: 10.1186/s12885-020-07267-5.
6
Could local surgery improve survival in de novo stage IV breast cancer?局部手术能否改善初诊 IV 期乳腺癌患者的生存？
BMC Cancer. 2018 Sep 11;18(1):885. doi: 10.1186/s12885-018-4767-x.
7
Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: A retrospective analysis.中国西南地区IV期乳腺癌女性患者原发肿瘤手术可改善生存：一项回顾性分析
Medicine (Baltimore). 2017 Jun;96(22):e7048. doi: 10.1097/MD.0000000000007048.
8
Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.激素受体状态可能影响IV期乳腺癌手术的生存获益：一项基于人群的研究。
Oncotarget. 2016 Oct 25;7(43):70991-71000. doi: 10.18632/oncotarget.11235.
9
Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.原发肿瘤切除术治疗初诊 IV 期乳腺癌患者可减轻局部症状并提高生活质量。
Ann Surg Oncol. 2020 Apr;27(4):1025-1033. doi: 10.1245/s10434-019-08092-2. Epub 2020 Jan 22.
10
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.转移性模式可区分新诊断 IV 期乳腺癌行原发性手术的生存获益：一项真实世界观察性研究。
Eur J Surg Oncol. 2019 Aug;45(8):1364-1372. doi: 10.1016/j.ejso.2019.02.013. Epub 2019 Feb 19.
引用本文的文献
1
Impact of cancer-directed surgery for gastric cancer patients with lung metastasis: a prognosis analysis.针对伴有肺转移的胃癌患者进行的肿瘤定向手术的影响：一项预后分析。
J Gastrointest Oncol. 2025 Jun 30;16(3):890-898. doi: 10.21037/jgo-2024-976. Epub 2025 Jun 27.
2
Development and validation of novel machine learning-based prognostic models and propensity score matching for comparison of surgical approaches in mucinous breast cancer.基于新型机器学习的预后模型的开发与验证以及倾向评分匹配用于黏液性乳腺癌手术方法比较
Front Endocrinol (Lausanne). 2025 Jun 3;16:1557858. doi: 10.3389/fendo.2025.1557858. eCollection 2025.
3
Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study.术后原发区域放疗对新发转移性乳腺癌生存的影响：一项回顾性研究
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251341195. doi: 10.1177/15330338251341195. Epub 2025 May 7.
4
Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.III期与初发性IV期乳腺癌患者生存结局的比较。
Cancer. 2025 May 15;131(10):e35891. doi: 10.1002/cncr.35891.
5
Assessment of Treatment Sequence in Patients With Stage III Breast Cancer.评估 III 期乳腺癌患者的治疗顺序。
J Surg Res. 2024 Oct;302:347-358. doi: 10.1016/j.jss.2024.07.071. Epub 2024 Aug 14.
6
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?HER2阳性癌症合并脑转移患者治疗的新前沿：放疗总是有效的吗？
Cancers (Basel). 2024 Jul 5;16(13):2466. doi: 10.3390/cancers16132466.
7
Personalized surgical recommendations and quantitative therapeutic insights for patients with metastatic breast cancer: Insights from deep learning.转移性乳腺癌患者的个性化手术建议和定量治疗见解：深度学习的启示
Cancer Innov. 2024 Apr 15;3(3):e119. doi: 10.1002/cai2.119. eCollection 2024 Jun.
8
Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".未经治疗的转移性乳腺癌患者的生存：“如果我什么都不做会怎样？”
Breast Cancer Res Treat. 2024 Jun;205(2):333-347. doi: 10.1007/s10549-024-07265-2. Epub 2024 Mar 5.
9
Analysis of the distinct features of metastasis male breast cancer and its effect on overall survival based on the SEER database compared with female breast cancer.基于监测、流行病学和最终结果（SEER）数据库，对比女性乳腺癌，分析男性转移性乳腺癌的独特特征及其对总生存期的影响。
Transl Cancer Res. 2023 Sep 30;12(9):2371-2378. doi: 10.21037/tcr-23-1175. Epub 2023 Sep 22.
10
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy.一线化疗的初治转移性乳腺癌患者原发肿瘤的局部区域治疗
Cancers (Basel). 2022 Dec 17;14(24):6237. doi: 10.3390/cancers14246237.
本文引用的文献
1
Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status.已知激素受体和HER2状态的IV期乳腺癌患者手术治疗的益处
Ann Surg Oncol. 2021 May;28(5):2646-2658. doi: 10.1245/s10434-020-09244-5. Epub 2020 Oct 30.
2
Role of Locoregional Treatment in De Novo Stage IV Breast Cancer.局部区域治疗在初治IV期乳腺癌中的作用
Clin Med Insights Oncol. 2020 Sep 17;14:1179554920942440. doi: 10.1177/1179554920942440. eCollection 2020.
3
A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.一种新的转移性乳腺癌分期系统可改善预后评估。
Ann Surg. 2022 Apr 1;275(4):784-792. doi: 10.1097/SLA.0000000000004231.
4
Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial.新发转移性乳腺癌患者原发肿瘤完整的局部区域治疗；ECOG-ACRIN 2108试验的评论与关注
Eur J Breast Health. 2020 Jun 8;16(3):158-159. doi: 10.5152/ejbh.2020.080620. eCollection 2020 Jul.
5
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.乳腺癌肝转移的肝切除术：内在亚型的影响。
Eur J Surg Oncol. 2020 Sep;46(9):1588-1595. doi: 10.1016/j.ejso.2020.03.214. Epub 2020 Mar 28.
6
Impact of breast surgery on survival of patients with stage IV breast cancer: a SEER population-based propensity score matching analysis.乳房手术对IV期乳腺癌患者生存的影响：一项基于监测、流行病学和最终结果（SEER）数据库人群的倾向评分匹配分析
PeerJ. 2020 Mar 18;8:e8694. doi: 10.7717/peerj.8694. eCollection 2020.
7
Individualized Prediction of Survival Benefit From Locoregional Surgical Treatment for Patients With Metastatic Breast Cancer.转移性乳腺癌患者局部区域手术治疗生存获益的个体化预测
Front Oncol. 2020 Feb 18;10:148. doi: 10.3389/fonc.2020.00148. eCollection 2020.
8
Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.将初发转移性乳腺癌 M1 分期细分，以更好地预测预后和原发肿瘤手术的反应。
J Natl Compr Canc Netw. 2019 Dec;17(12):1521-1528. doi: 10.6004/jnccn.2019.7332.
9
Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis.局部区域性手术治疗可改善除脑转移以外的单发远处转移的原发性转移性乳腺癌患者的预后。
Breast. 2019 Jun;45:104-112. doi: 10.1016/j.breast.2019.03.006. Epub 2019 Mar 23.
10
De-novo metastatic breast cancers with or without primary tumor resection - A 10-year study.有或无原发性肿瘤切除的新发转移性乳腺癌——一项10年研究。
Cancer Treat Res Commun. 2019;19:100118. doi: 10.1016/j.ctarc.2019.100118. Epub 2019 Jan 21.
Zotero 插件